<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02637375</url>
  </required_header>
  <id_info>
    <org_study_id>IRB15-0848</org_study_id>
    <nct_id>NCT02637375</nct_id>
  </id_info>
  <brief_title>A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer</brief_title>
  <official_title>A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Based on preclinical data implicating GR, AR, and JAK/STAT activation as potent mechanisms of&#xD;
      breast cancer cell survival despite chemotherapy administration (i.e. chemotherapy&#xD;
      resistance), the study will test a novel approach for improving chemotherapy effectiveness by&#xD;
      adding Hsp90 inhibition to antagonize the anti-apoptotic signaling pathways that are&#xD;
      initiated via GR, AR, and JAK/STAT activation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      STUDY OBJECTIVES&#xD;
&#xD;
      Primary:&#xD;
&#xD;
      • To determine tumor GR, AR, JAK and other Hsp90 client protein expression before and after&#xD;
      two weeks of ganetespib monotherapy&#xD;
&#xD;
      Secondary:&#xD;
&#xD;
        -  To determine the pathological Complete Response (pCR) rate associated with weekly&#xD;
           treatment of ganetespib plus paclitaxel followed by the combination treatment of&#xD;
           doxorubicin plus cyclophosphamide&#xD;
&#xD;
        -  To characterize the toxicity of study treatment&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study never opened (terminated as study drug no longer available)&#xD;
  </why_stopped>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in GR protein</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pathological Complete Response (pCR) rate</measure>
    <time_frame>6 month</time_frame>
    <description>Defined as absence of invasive carcinoma in both the breast and axilla at the time of surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ganetespib toxicity</measure>
    <time_frame>14 weeks</time_frame>
    <description>Side effects related to Ganetespib as graded per Common Terminology Criteria for Adverse Events (CTCAE) version 4</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive ganetespib monotherapy for two weeks followed by twelve weeks of ganetespib/paclitaxel therapy followed by 4 bi-weekly doses of doxorubicin/cyclophosphamide therapy followed by surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ganetespib</intervention_name>
    <arm_group_label>Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <arm_group_label>Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <arm_group_label>Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <arm_group_label>Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Invasive carcinoma of the breast&#xD;
&#xD;
          -  ER negative and PR negative tumors defined as &lt; 1% of tumor nuclei that are&#xD;
             immunoreactive for ER and PR&#xD;
&#xD;
          -  HER2 non-overexpressing status documented as:&#xD;
&#xD;
          -  FISH ratio of less than 2.0, OR&#xD;
&#xD;
          -  IHC staining of 0 or 1+&#xD;
&#xD;
          -  No evidence of distant metastatic disease. Patients with regional lymph node&#xD;
             involvement are eligible.&#xD;
&#xD;
          -  &gt;18 years old&#xD;
&#xD;
          -  Female&#xD;
&#xD;
          -  No prior treatment for the disease under study&#xD;
&#xD;
          -  No prior treatment within 5 years for any other cancer including chemotherapy, surgery&#xD;
             (except for diagnostic biopsy), radiotherapy, hormonal therapy, or investigational&#xD;
             agents, unless curative treatment of non-melanoma skin-cancer or in-situ cancer&#xD;
&#xD;
          -  Able to understand and sign an informed consent (or have a legal representative who is&#xD;
             able to do so)&#xD;
&#xD;
          -  Clinically or radiologically measureable disease in the breast after diagnostic&#xD;
             biopsy, defined as longest diameter greater than or equal to 2cm&#xD;
&#xD;
          -  Willing to undergo three mandatory core biopsies after diagnosis to obtain tissue for&#xD;
             biologic expression profiling.&#xD;
&#xD;
          -  An Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1&#xD;
&#xD;
          -  Adequate bone marrow reserves as evidenced by:&#xD;
&#xD;
          -  Leukocytes &gt; 3,000/μL&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt; 1,500/μL without the use of hematopoietic growth&#xD;
             factors,&#xD;
&#xD;
          -  Platelet count &gt; 100,000/μL, and&#xD;
&#xD;
          -  Hemoglobin &gt; 9 g/dL&#xD;
&#xD;
          -  Adequate hepatic function as evidenced by:&#xD;
&#xD;
          -  Serum total bilirubin within institutional normal limits&#xD;
&#xD;
          -  Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline&#xD;
             phosphatase less than or equal to 2.5 × ULN&#xD;
&#xD;
          -  Adequate renal function as evidenced by a serum creatinine within ULN or creatinine&#xD;
             clearance &gt; 60 mL/min/1.73 m2 for patients with creatinine levels above institutional&#xD;
             normal&#xD;
&#xD;
          -  Eligible for treatment with paclitaxel, doxorubicin and cyclophosphamide&#xD;
&#xD;
          -  If of childbearing potential, are willing to abstain from sexual intercourse or to use&#xD;
             an effective form of contraception (e.g., a double-barrier method) during the study&#xD;
             and for 90 days following the last dose of ganetespib&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • Patients may not be receiving any other investigational agents.&#xD;
&#xD;
               -  Patients may not have a known hypersensitivity to any of the components of&#xD;
                  ganetespib&#xD;
&#xD;
               -  Patients may not have a history of severe allergic reactions to paclitaxel or&#xD;
                  other drugs formulated in Cremaphor® EL.&#xD;
&#xD;
               -  Patients with a QTc &gt; 470 ms, a family history of long QT Syndrome, and those on&#xD;
                  medications known to cause Torsades de Pointes will be excluded from the study.&#xD;
&#xD;
               -  Patients may not have an uncontrolled intercurrent illness including, but not&#xD;
                  limited to, ongoing or active infection, symptomatic congestive heart failure,&#xD;
                  unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social&#xD;
                  situations that would limit compliance with study requirements.&#xD;
&#xD;
               -  Patients may not have New York Heart Association (NYHA) Class III or IV&#xD;
                  congestive heart failure or left ventricular ejection fraction (LVEF) &lt; 50%.&#xD;
&#xD;
               -  As patients with immune deficiency are at increased risk of lethal infections&#xD;
                  when treated with marrow-suppressive therapy, HIV-positive patients receiving&#xD;
                  combination anti-retroviral therapy are excluded from the study.&#xD;
&#xD;
               -  Patients may not have a need for chronic systemic steroid therapy&#xD;
&#xD;
               -  Patients may not be pregnant or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rita Nanda, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>May 2016</verification_date>
  <study_first_submitted>December 17, 2015</study_first_submitted>
  <study_first_submitted_qc>December 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2015</study_first_posted>
  <last_update_submitted>May 26, 2016</last_update_submitted>
  <last_update_submitted_qc>May 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>triple-negative breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

